Cacz885v2301- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating The Efficacy And Safety Of Canakinumab In Combination With Docetaxel Versus Placebo In Combination With Docetaxel In Subjects With Non-Small Cell Lung Cancer (Nsclc)
Posted Date: Oct 10, 2019
- Investigator: Muhammad Riaz
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The goal of this study is to evaluate canakinumab in combination with docetaxel and the role of IL-1ß inhibition in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy
Criteria:
To Be Eligible: >18 Years Of Age, Confirmed Advanced/Metastatic Nsclc, Ecog 0 Or 1, No Other Malignancy Within 3 Years, No Significant Uncontrolled Medical Condition, Nonpregnant/Nonbreastfeeding
Keywords:
Lung Cancer, Oncology, Nsclc
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com